Literature DB >> 26765933

Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model.

Lauren M Federici1, Izabela Facco Caliman2, Andrei I Molosh3, Stephanie D Fitz4, William A Truitt2, Pascal Bonaventure5, Janet S Carpenter6, Anantha Shekhar3, Philip L Johnson7.   

Abstract

Distressing symptoms such as hot flashes and sleep disturbances affect over 70% of women approaching menopause for an average of 4-7 years, and recent large cohort studies have shown that anxiety and stress are strongly associated with more severe and persistent hot flashes and can induce hot flashes. Although high estrogen doses alleviate symptoms, extended use increases health risks, and current non-hormonal therapies are marginally better than placebo. The lack of effective non-hormonal treatments is largely due to the limited understanding of the mechanisms that underlie menopausal symptoms. One mechanistic pathway that has not been explored is the wake-promoting orexin neuropeptide system. Orexin is exclusively synthesized in the estrogen receptor rich perifornical hypothalamic region, and has an emerging role in anxiety and thermoregulation. In female rodents, estrogens tonically inhibit expression of orexin, and estrogen replacement normalizes severely elevated central orexin levels in postmenopausal women. Using an ovariectomy menopause model, we demonstrated that an anxiogenic compound elicited exacerbated hot flash-associated increases in tail skin temperature (TST, that is blocked with estrogen), and cellular responses in orexin neurons and efferent targets. Furthermore, systemic administration of centrally active, selective orexin 1 or 2 and dual receptor antagonists attenuated or blocked TST responses, respectively. This included the reformulated Suvorexant, which was recently FDA-approved for treating insomnia. Collectively, our data support the hypothesis that dramatic loss of estrogen tone during menopausal states leads to a hyperactive orexin system that contributes to symptoms such as anxiety, insomnia, and more severe hot flashes. Additionally, orexin receptor antagonists may represent a novel non-hormonal therapy for treating menopausal symptoms, with minimal side effects.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cutaneous; Estrogen; Hot flash; Hypocretin; Hypothalamus; Menopause; Norepinephrine; Orexin; Serotonin; Thermoregulation

Mesh:

Substances:

Year:  2015        PMID: 26765933      PMCID: PMC4752911          DOI: 10.1016/j.psyneuen.2015.12.011

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  56 in total

1.  Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome.

Authors:  R P Allen; E Mignot; B Ripley; S Nishino; C J Earley
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

2.  Ethanol and nicotine interaction within the posterior ventral tegmental area in male and female alcohol-preferring rats: evidence of synergy and differential gene activation in the nucleus accumbens shell.

Authors:  William A Truitt; Sheketha R Hauser; Gerald A Deehan; Jamie E Toalston; Jessica A Wilden; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Psychopharmacology (Berl)       Date:  2014-08-26       Impact factor: 4.530

3.  Alpha 2-adrenergic mechanism in menopausal hot flushes.

Authors:  R R Freedman; S Woodward; S C Sabharwal
Journal:  Obstet Gynecol       Date:  1990-10       Impact factor: 7.661

4.  Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms?

Authors:  U Baerug; T Winge; G Nordland; E Faber-Swensson; K Heldaas; B Norling; S Larsen; J C Arce
Journal:  Climacteric       Date:  1998-09       Impact factor: 3.005

5.  Circadian-dependent and circadian-independent behavioral actions of hypocretin/orexin.

Authors:  Rodrigo A España; Stacey Plahn; Craig W Berridge
Journal:  Brain Res       Date:  2002-07-12       Impact factor: 3.252

6.  Hypothalamic-pituitary-adrenal responses to centrally administered orexin-A are suppressed in pregnant rats.

Authors:  P J Brunton; J A Russell
Journal:  J Neuroendocrinol       Date:  2003-07       Impact factor: 3.627

7.  Measuring hot flashes: summary of a National Institutes of Health workshop.

Authors:  Heather G Miller; Rose Maria Li
Journal:  Mayo Clin Proc       Date:  2004-06       Impact factor: 7.616

8.  Premenstrual syndrome as a predictor of menopausal symptoms.

Authors:  E W Freeman; M D Sammel; P J Rinaudo; L Sheng
Journal:  Obstet Gynecol       Date:  2004-05       Impact factor: 7.661

9.  Plasma orexin-A levels in postmenopausal women: possible interaction with estrogen and correlation with cardiovascular risk status.

Authors:  M Sh E A El-Sedeek; A A Korish; M M Deef
Journal:  BJOG       Date:  2010-01-26       Impact factor: 6.531

10.  The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.

Authors:  Anthony L Gotter; Christopher J Winrow; Joseph Brunner; Susan L Garson; Steven V Fox; Jacquelyn Binns; Charles M Harrell; Donghui Cui; Ka Lai Yee; Mark Stiteler; Joanne Stevens; Alan Savitz; Pamela L Tannenbaum; Spencer J Tye; Terrence McDonald; Leon Yao; Scott D Kuduk; Jason Uslaner; Paul J Coleman; John J Renger
Journal:  BMC Neurosci       Date:  2013-08-28       Impact factor: 3.288

View more
  3 in total

1.  Effects of Moderate-Intensity Physical Training on Skeletal Muscle Substrate Transporters and Metabolic Parameters of Ovariectomized Rats.

Authors:  Taciane Maria Melges Pejon; Pedro Paulo Menezes Scariot; Heloísa Sobreiro Selistre-de-Araujo; Claudio Alexandre Gobatto; Anabelle Silva Cornachione; Wladimir Rafael Beck
Journal:  Metabolites       Date:  2022-04-29

2.  Anxiogenic CO2 stimulus elicits exacerbated hot flash-like responses in a rat menopause model and hot flashes in postmenopausal women.

Authors:  Lauren M Federici; Sarah Dorsey Roth; Connie Krier; Stephanie D Fitz; Todd Skaar; Anantha Shekhar; Janet S Carpenter; Philip L Johnson
Journal:  Menopause       Date:  2016-11       Impact factor: 2.953

3.  Sexually Dimorphic Changes of Hypocretin (Orexin) in Depression.

Authors:  Jing Lu; Juan Zhao; Rawien Balesar; Rolf Fronczek; Qiong-Bin Zhu; Xue-Yan Wu; Shao-Hua Hu; Ai-Min Bao; Dick F Swaab
Journal:  EBioMedicine       Date:  2017-03-31       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.